HomeArticle

Immortal True Dragon establishes a $40 million longevity fund, focusing on investment in cutting-edge life extension technologies.

36氪品牌2026-03-09 15:28
The Immortal True Dragon Fund promotes radical life extension technologies, has made strategic layouts in four major frontier fields, and has invested in more than 20 start-ups.

Singapore-headquartered mission-driven fund Immortal Dragon recently announced that it will promote the development of radical life extension technologies with a unique investment philosophy. Currently, the fund has assets under management of 40 million US dollars, committed to driving breakthroughs in longevity science and healthy lifespan research through the power of capital.

From the perspective of Immortal Dragon, aging and death are technical challenges that can be overcome through scientific innovation. This philosophy runs through all its investment decisions, making it prioritize social impact over pure financial returns when making portfolio layouts.

Layout of Cutting-edge Technologies in Four Strategic Directions

Up to now, Immortal Dragon has invested in more than 20 cutting-edge start-ups in the industry, focusing on four strategic areas:

The first is Replacement technology, including pioneering researches such as xenotransplantation, cryopreservation, 3D bioprinting and biological tissue and organ replacement, which replaces aging and damaged parts with well-functioning tissues or organs; the second is Neural and Brain Rejuvenation technology, covering cutting-edge researches such as neuron regeneration, neurodegenerative disease intervention and cognitive function enhancement, aiming to fundamentally delay or even reverse the brain aging process; the third is Reproduction Tech, including directions such as in vitro gametogenesis (IVG), artificial womb, assisted reproduction and embryo technology, fertility preservation and ovarian aging intervention, dedicated to extending reproductive lifespan and expanding the boundary of human fertility; the fourth is Cells and Gene Therapy, including stem cell therapy, cell reprogramming, gene editing and novel delivery methods, to intervene and treat the root causes of aging and related diseases.

Boyang, the founder of the fund, said: "Whether it is cutting-edge scientific research or creating a better environment for scientific research, we are committed to looking for investment opportunities that can bring real impact." He also emphasized that the fund not only focuses on radical cutting-edge technologies, but also pays attention to the infrastructure construction that supports technology implementation, such as special economic zones and other supporting facilities.

Mission-driven, Impact First

The first phase fund of Immortal Dragon is mainly funded by the founding team's own capital, with only one external limited partner, which enables it to quickly and decisively allocate capital to the most potential projects. This model also enables it to support key projects that are ignored by mainstream capital but have long-term value.

"We are a mission-driven fund, which means that Immortal Dragon values impact more than financial returns," Boyang said in a recent interview, "I invest in the longevity field because I want to see real breakthroughs in this sector."

It is worth mentioning that Boyang himself is one of the first 300 individuals worldwide to receive the Minicircle follistatin gene therapy, a choice that demonstrates the fund's determination to embrace cutting-edge science. "Gene therapy is a personal attempt, but it truly reflects our risk appetite and support for the longevity cause," he explained, "We have strong motivation to support the first batch of longevity enterprises to achieve profitability, so as to promote broader investment progress."

Actively Promote the Development of Global Longevity Technology

In addition to capital layout, Immortal Dragon is also actively fostering the global ecosystem for the development of longevity technology. The fund continues to invest in education promotion and community building, including translating scientific speeches and books in the longevity field, hosting and producing original Chinese longevity podcast content, funding scientific research projects at top anti-aging medical schools such as Stanford University and the University of Copenhagen, and providing support for international anti-aging summits and organizations such as Vitalist Bay, ARDD 2025, and the Alzheimer's Association of the United States. From the perspective of Immortal Dragon, the progress of the longevity industry requires not only capital investment, but also the awakening of public awareness and the improvement of supporting infrastructure.

Professor Peter Lidsky from the Department of Biomedical Sciences of City University of Hong Kong recalled: "I was deeply inspired when I met the Immortal Dragon team at the Vitalist Bay conference in Berkeley earlier this year. These young, brave and energetic people are working hard to solve the major challenge facing humanity — aging. They have provided great help in translating my lectures into Chinese, and I look forward to deeper cooperation in the future."

Aubrey de Grey, Chairman of the LEV Foundation, also said: "It is a pleasure to get to know the Immortal Dragon team. For many years, I have been regretful that few people in China pay attention to the longevity field, and now this situation is changing. This team is bringing my work and the work of other researchers to the Chinese public, and I am very pleased to see them invest in promising longevity start-ups."

As a practitioner of mission-driven investment, Immortal Dragon is taking a posture of breaking through the status quo, providing a new perspective for human healthy lifespan, expanding the boundary of science, and continuing the torch of the life extension cause.